At a time when India is facing the second wave of corona epidemic and the central government is feeling the need for more and more corona vaccine dose, the serum institute that makes Vaccine Covishield needs around Rs 3000 crore to increase its production. . Serum Institute of India (SII) Chief Executive Officer (CEO) Adar Poonawalla (Adar Poonawalla) said this on Tuesday. Poonawala, who had earlier said that SII agreed to supply the initial 100 million doses at a significantly discounted rate, has now said that the company should have made bigger profits than it has now to reinvest this amount for production and facilities Can be given and more doses of vaccine can be made available.
Speaking to NewsBust, Poonawala said, “We are supplying the vaccine in the Indian market at a rate of around Rs 150-160 while the average price of the vaccine is around $ 20 (Rs 1,500).” On the request of the Narendra Modi government, we are providing the vaccine at a discounted rate. It is not that we are not making profits but we are not making super profit which is important in terms of re-investment. ‘
Earlier, Adar Poonawala on Sunday urged countries waiting for the Kovid-19 vaccine to be patient and said that the company was prioritizing India’s needs. He wrote in a tweet that besides meeting the needs of India, the company is trying its best to meet the needs of the rest of the world as well. Poonawala tweeted, “Dear countries and governments, as you await the supply of Kovishield, I humbly request you to please be patient, Serum Institute India was instructed to prioritize India’s vast needs. And with this, we are trying our best to meet the needs of the rest of the world. ”